MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: hepatocellular carcinoma
MedXY News
EnglishTag

hepatocellular carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations
Gastroenterologycirrhosischronic hepatitis B

Reevaluating EASL 2025 Criteria: Benefits of Nucleos(t)ide Analogues in Chronic Hepatitis B Beyond Current Recommendations

By MedXY|Oct 20, 2026

This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.

Liver Transplantation for Hepatocellular Carcinoma: Prognostic Impact of Complete Pathologic Response and Influence of Treatment Modality—A US National Database Study
Clinical Updatescomplete pathologic response
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
hepatocellular carcinoma

Liver Transplantation for Hepatocellular Carcinoma: Prognostic Impact of Complete Pathologic Response and Influence of Treatment Modality—A US National Database Study

By MedXY|Oct 6, 2026

Complete pathologic response (cPR) after locoregional therapies notably improves survival in hepatocellular carcinoma (HCC) patients undergoing liver transplantation. Yttrium-90 radioembolization shows superior cPR rates, particularly when

TESERA: Advancing Morphologic Subtyping and Prognostic Stratification in Hepatocellular Carcinoma Using H&E Whole-Slide Images
newsComputational Pathologyhepatocellular carcinoma

TESERA: Advancing Morphologic Subtyping and Prognostic Stratification in Hepatocellular Carcinoma Using H&E Whole-Slide Images

By MedXY|Oct 6, 2026

TESERA leverages computational pathology to classify hepatocellular carcinoma into biologically distinct morphologic subtypes from standard H&E slides, offering accurate prognosis stratification competitive with clinical and molecular m

Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma: Evidence, Outcomes, and Clinical Perspectives
Clinical Updatesdownstaging therapyhepatocellular carcinoma

Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma: Evidence, Outcomes, and Clinical Perspectives

By MedXY|Oct 5, 2026

This review synthesizes recent evidence on immune checkpoint inhibitor (ICI)-based downstaging therapy for hepatocellular carcinoma (HCC) beyond Milan criteria prior to liver transplantation, highlighting improved oncologic outcomes alongsi

Designing Rigorous Trials of Systemic Therapy with Surgery and Locoregional Treatment in Hepatocellular Carcinoma: Key Recommendations from an HCC-Live Expert Consensus
Gastroenterology系统性治疗perioperative

Designing Rigorous Trials of Systemic Therapy with Surgery and Locoregional Treatment in Hepatocellular Carcinoma: Key Recommendations from an HCC-Live Expert Consensus

By MedXY|Sep 29, 2026

A multidisciplinary consensus provides practical, trial-design focused recommendations for testing systemic therapies around surgery or combined with locoregional treatment in hepatocellular carcinoma, emphasizing patient selection, endpoin

Steatotic Liver Disease Risk Scores for Predicting Cirrhosis and Hepatocellular Carcinoma: A Comprehensive Clinical Review
Clinical UpdatesNon-invasive testscirrhosis

Steatotic Liver Disease Risk Scores for Predicting Cirrhosis and Hepatocellular Carcinoma: A Comprehensive Clinical Review

By MedXY|Sep 24, 2026

This review assesses the clinical utility of steatotic liver disease risk scores in predicting cirrhosis and hepatocellular carcinoma, highlighting the superior performance of the SAFE score for cirrhosis and challenges in HCC risk predicti

Reevaluating Immune Tolerant Phase in Chronic Hepatitis B: High Transition Rates to Immune Active Disease and Clinical Implications from the RADICAL Consortium
Gastroenterologychronic hepatitis BFibrosis progression

Reevaluating Immune Tolerant Phase in Chronic Hepatitis B: High Transition Rates to Immune Active Disease and Clinical Implications from the RADICAL Consortium

By MedXY|Sep 23, 2026

The RADICAL consortium’s large-scale study reveals a high long-term transition rate from immune tolerant to immune active chronic hepatitis B, especially in patients with high-normal ALT, suggesting the need for closer monitoring and

Unraveling the S1P-TREM2 Axis: A Novel Ferroptosis-Resistance Mechanism Driving Immunosuppressive Neutrophils and Tumour Progression in Hepatocellular Carcinoma
Gastroenterologyferroptosisimmunotherapy resistance

Unraveling the S1P-TREM2 Axis: A Novel Ferroptosis-Resistance Mechanism Driving Immunosuppressive Neutrophils and Tumour Progression in Hepatocellular Carcinoma

By MedXY|Sep 12, 2026

This study reveals how the S1P-TREM2-NRF2 signaling pathway protects tumor-associated neutrophils from ferroptosis, sustaining immunosuppression and promoting hepatocellular carcinoma progression, offering new therapeutic avenues.

Refining Prognostic Stratification in Hepatocellular Carcinoma: The Critical Role of Vascular Invasion Type and Extent
General Surgeryhepatic veinprognostic stratification

Refining Prognostic Stratification in Hepatocellular Carcinoma: The Critical Role of Vascular Invasion Type and Extent

By MedXY|Sep 5, 2026

This study elucidates how distinct patterns and gradations of vascular invasion in hepatocellular carcinoma differentially impact recurrence timing and overall survival, enabling improved postoperative risk stratification.

Decoding CPEB3-Regulated Alternative Polyadenylation: A New Genetic Lens on Hepatocellular Carcinoma Prognosis
GastroenterologyAlternative PolyadenylationCPEB3

Decoding CPEB3-Regulated Alternative Polyadenylation: A New Genetic Lens on Hepatocellular Carcinoma Prognosis

By MedXY|Sep 5, 2026

This article explores how genetic variants affect CPEB3-mediated alternative polyadenylation in hepatocellular carcinoma, revealing potential prognostic markers and therapeutic targets to improve patient survival.

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC
Gastroenterologygut microbiotametabolomics

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC

By MedXY|Aug 22, 2026

Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.

Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma
GastroenterologyNEK7Lenvatinib resistance

Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma

By MedXY|Aug 21, 2026

NEK7 promotes acquired lenvatinib resistance in hepatocellular carcinoma by phosphorylating EGFR at serine 1070, activating key signaling pathways. Blocking this interaction offers a promising therapeutic avenue to counteract resistance.

Decoding Hepatocellular Carcinoma in Fontan-Associated Liver Disease: Genomic and Transcriptomic Insights
CardiologyFontan-associated liver diseasegenomics

Decoding Hepatocellular Carcinoma in Fontan-Associated Liver Disease: Genomic and Transcriptomic Insights

By MedXY|Aug 12, 2026

This article explores the unique genomic and transcriptomic features of hepatocellular carcinoma in Fontan-associated liver disease, revealing distinct mutation patterns and poor-prognosis molecular subtypes that inform disease mechanisms a

BEACON-HCC: A North American consensus reshaping treatment allocation for hepatocellular carcinoma
GastroenterologyBEACON-HCClocoregional therapy

BEACON-HCC: A North American consensus reshaping treatment allocation for hepatocellular carcinoma

By MedXY|Aug 9, 2026

BEACON-HCC is a multidisciplinary, evidence-based North American consensus that updates HCC treatment allocation—integrating tumor biology, nuanced intrahepatic burden, vascular invasion, and newer modalities (EBRT, TARE, systemic–locoregio

Extracellular Vesicles as Liquid Biopsy Biomarkers Predicting Immune Checkpoint Therapy Resistance in Hepatocellular Carcinoma
Gastroenterologyimmune checkpoint inhibitorsimmunotherapy resistance

Extracellular Vesicles as Liquid Biopsy Biomarkers Predicting Immune Checkpoint Therapy Resistance in Hepatocellular Carcinoma

By MedXY|Aug 9, 2026

Circulating extracellular vesicles carrying PD-1, PD-L1, and CTLA-4 can non-invasively predict responses and early resistance to immune checkpoint inhibitors in advanced hepatocellular carcinoma, improving patient stratification and managem

RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma
GastroenterologyCancer StemnessCTNNB1 mutation

RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma

By MedXY|Jul 31, 2026

RIPPLY1 suppresses cancer stemness by targeting TBX19, improving prognosis in CTNNB1-mutated hepatocellular carcinoma through inhibition of tumor progression.

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial
Gastroenterologyhepatocellular carcinomarandomized clinical trial

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial

By MedXY|Jul 30, 2026

The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellula

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen
Gastroenterologychronic hepatitis BHBsAg seroclearance

Long-term Risk of Hepatocellular Carcinoma After Clearance of Hepatitis B Surface Antigen

By MedXY|Jul 14, 2026

This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients
Clinical Updatesalpha-fetoproteincancer biomarkers

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

By MedXY|Jul 7, 2026

Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study
Clinical UpdatesDPP‑4 inhibitorsGLP-1 receptor agonists

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

By MedXY|Jul 5, 2026

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental

1 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models